Sign in
CompletedNo phase

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

Key facts

Who runs it
Boston Medical Center
Where
Boston and Carrboro, United StatesSee the 2 sites
Trial code
Status
Completed
People taking part
46 people enrolled
Started
1 Dec 2018
Ended
8 May 2024
Type of study
Observational, 3 groups
Treatments tested
  • Pharmacokinetic analysis
  • Safety and Efficacy
  • Genetic and epigenetic analysis
  • Breast milk analysis
Record updated
4 November 2024

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Pregnant women between 6 - 30 6/7 weeks gestation, receiving prenatal care at Boston Medical Center (BMC) or the University of North Carolina (UNC)
  • Plan to deliver infant at BMC or UNC
  • Diagnosis of opioid use disorder (OUD) or alcohol use disorder (AUD) in the current pregnancy on prescribed oral or extended-release naltrexone; or buprenorphine/naloxone for the treatment of OUD
  • English speaking
  • Singleton pregnancy

Who cannot take part

  • OUD on prescribed methadone, or no maintenance medication
  • Severe psychiatric illness or cognitively impairing ability to provide informed consent
  • OUD on Subutex formulation of buprenorphine
  • Current maternal incarceration
  • Women who present for care >31 0/7 weeks
  • Multiple gestation pregnancy

Where in United States

  • Boston Medical CenterBoston, United States
  • University of North Carolina-Chapel HillCarrboro, United States

About the trial

What the trial wants to find out

This is a multi-center prospective comparative cohort study examining the safety, efficacy, pharmacokinetics, and pharmacogenomics of naltrexone for pregnant women with opioid use disorder. Pregnancy, delivery, and maternal and infant outcomes to 12 months post-delivery will be examined and compared with a cohort treated with buprenorphine/naloxone.

The 3 groups in the trial

  • Naltrexone

    Pregnant women with opioid use disorder on prescribed oral or extended-release naltrexone and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This group will also receive safety and efficacy interventions.

    Treatment: Pharmacokinetic analysis, Safety and Efficacy, Genetic and epigenetic analysis, and Breast milk analysis

  • Buprenorphine/Naloxone

    Pregnant women with opioid use disorder on prescribed buprenorphine/naloxone and their infants. Biospecimens collected from this group will undergo genetic and epigenetic analysis and the group will also receive safety and efficacy interventions.

    Treatment: Safety and Efficacy and Genetic and epigenetic analysis

  • Naltrexone - alcohol use disorder

    Pregnant women with alcohol use disorder on prescribed naltrexone (oral or extended-release) and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This exploratory group will also receive safety and efficacy interventions.

    Treatment: Pharmacokinetic analysis, Genetic and epigenetic analysis, and Breast milk analysis

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety, Efficacy, Pharmacokinetics, and Pharmacogenomics of Extended-Release Naltrexone in Pregnant Women
Record updated
4 November 2024